Sibeprenlimab, a monoclonal antibody, is the only IgA nephropathy treatment option to selectively inhibit the activity of a ...

The U.S. Food and Drug Administration has approved Otsuka's injectable drug to treat patients with a potentially ...

Diabetes affects how the body uses glucose, also known as blood sugar. It can mean that there is too much sugar in the blood.

Chronic Kidney Disease (CKD) is quietly rising as a global health crisis, and the latest research reveals just how serious ...

Researchers at The Johns Hopkins Medicine say they have developed a new electronic medical records-based tool that should ...

Testosterone therapy was associated with lower risks for acute kidney injury and all-cause mortality among patients with hypogonadism and diabetes.

A new FDA approval for a first-in-class drug has vaulted Otsuka into immunoglobulin A nephropathy (IgAN), an increasingly competitive kidney disease field targeted by multiple biopharma companies.

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

Investigators assessed sex differences in the risk for major cardiovascular events (MACE+) among patients with anemia of non-dialysis chronic kidney disease (CKD).

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today announce the U ...

In a rapidly heating market, Otsuka is the first to secure FDA clearance for an "anti-APRIL" therapy targeting IgA ...